Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Alexander M. Sele"'
Autor:
Thomas Bohnacker, Andrea E. Prota, Florent Beaufils, John E. Burke, Anna Melone, Alison J. Inglis, Denise Rageot, Alexander M. Sele, Vladimir Cmiljanovic, Natasa Cmiljanovic, Katja Bargsten, Amol Aher, Anna Akhmanova, J. Fernando Díaz, Doriano Fabbro, Marketa Zvelebil, Roger L. Williams, Michel O. Steinmetz, Matthias P. Wymann
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
Buparlisib/BKM120 is in phase 3 clinical trials as a phosphoinositide 3-kinase (PI3K) inhibitor. Here, Bohnackeret al. combine chemical biology and structural biology approaches to segregate BKM120’s biological actions, and suggest that it causes m
Externí odkaz:
https://doaj.org/article/a5212909a4a7490db4d79600c172c822
Autor:
Chiara Borsari, Doriano Fabbro, Petra Hillmann, Florent Beaufils, Thomas Bohnacker, Matthias P. Wymann, Denise Rageot, Ivan Buslov, Erhan Keles, Alexander M. Sele, Anna Melone, Paul Hebeisen
Publikováno v:
ACS Medicinal Chemistry Letters
The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is a critical regulator of cell growth and is frequently hyperactivated in cancer. Therefore, PI3K inhibitors represent a valuable asset in cancer therapy. Herein we
Autor:
Petra Hillmann, Thomas Bohnacker, Matthias P. Wymann, Alix Dall’Asen, Eileen Jackson, Anna Melone, Florent Beaufils, Denise Rageot, Jean-Baptiste Langlois, Alexander M. Sele, Doriano Fabbro, Paul Hebeisen, Chiara Borsari
Publikováno v:
Journal of Medicinal Chemistry. 62:8609-8630
The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin d
Autor:
Denise Rageot, Thomas Bohnacker, Erhan Keles, Jacob A. McPhail, Reece M. Hoffmann, Anna Melone, Chiara Borsari, Rohitha Sriramaratnam, Alexander M. Sele, Florent Beaufils, Paul Hebeisen, Doriano Fabbro, Petra Hillmann, John E. Burke, Matthias P. Wymann
Publikováno v:
Journal of Medicinal Chemistry. 62:6241-6261
Autor:
Matthias P. Wymann, Doriano Fabbro, Wolfgang Löscher, Kerstin Römermann, Andreas Noack, Petra Hillmann, Florent Beaufils, Anna Melone, Claudia Brandt, Alexander M. Sele, Denise Rageot, Leon A. Öhler
Publikováno v:
Neuropharmacology. 140:107-120
The mTOR signaling pathway has emerged as a possible therapeutic target for epilepsy. Clinical trials have shown that mTOR inhibitors such as everolimus reduce seizures in tuberous sclerosis complex patients with intractable epilepsy. Furthermore, ac
Autor:
Alexander M. Sele, Jean-Baptiste Langlois, Denise Rageot, Petra Hillmann, Marketa Zvelebil, John E. Burke, Paul Hebeisen, Anna Melone, Chiara Borsari, Matthias P. Wymann, Florent Beaufils, Wolfgang Löscher, Doriano Fabbro, Thomas Bohnacker
Publikováno v:
Journal of medicinal chemistry. 61(22)
Mechanistic target of rapamycin (mTOR) promotes cell proliferation, growth, and survival and is overactivated in many tumors and central nervous system disorders. PQR620 (3) is a novel, potent, selective, and brain penetrable inhibitor of mTORC1/2 ki
Autor:
Davide Rossi, Filippo Spriano, Andrea Rinaldi, Valter Gattei, Emanuele Zucca, Luciano Cascione, Alberto J. Arribas, Andreas Wicki, Massimo Broggini, Petra Hillmann, Barbara Dossena, Reto Ritschard, M. Taborelli, Antonella Zucchetto, Georg Stussi, Eugenio Gaudio, Francesco Bertoni, Francesca Guidetti, Laura Carrassa, Denise Rageot, Doriano Fabbro, Roberta Bordone Pittau, Florent Beaufils, Alexander M. Sele, Elena Bernasconi, Anastasios Stathis, Francesca Rossi, Ivo Kwee, Vladimir Cmiljanovic, Matthias P. Wymann, Chiara Tarantelli
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(1)
Purpose: Activation of the PI3K/mTOR signaling pathway is recurrent in different lymphoma types, and pharmacologic inhibition of the PI3K/mTOR pathway has shown activity in lymphoma patients. Here, we extensively characterized the in vitro and in viv
Autor:
Paul A. Keller, Alexander M. Sele, Renate Griffith, Rachada Haritakun, Anthony C. Willis, John B. Bremner
Publikováno v:
ChemInform. 47
The allylation of indirubin produced the expected indolic N′-allylindirubin and N,N′-diallylindirubin derivatives in moderate yields, together with the corresponding N-substituted isatin products. At higher temperatures, the base-initiated reacti
Autor:
Denise Rageot, Alexander M. Sele, Anna Melone, Jürgen Mestan, Petra Hillmann, Matthias P. Wymann, Florent Beaufils, Marc Lang, Doriano Fabbro, Thomas Bohnacker, Paul Hebeisen
Publikováno v:
Cancer Research. 77:140-140
The PI3K/AKT/mTOR signaling pathway plays a fundamental role in cell proliferation, growth and survival and aberrant activation of this signaling pathway has been shown to drive the progression of malignant tumors.[1] Drugs targeting the pathway at m
Autor:
Eileen Jackson, Jean-Baptiste Langlois, Thomas Bohnacker, Matthias P. Wymann, Anna Melone, Alexander M. Sele, Denise Rageot, Doriano Fabbro, Paul Hebeisen, Florent Beaufils
Publikováno v:
Cancer Research. 77:153-153
Class I phosphoinositide 3-kinases (PI3Ks) are lipid kinases, produce PtdIns(3,4,5)P3 and trigger intracellular signaling pathways that are vital to cell growth, proliferation, survival and migration. Constitutive activation of PI3K is frequently obs